Significantly more patients with pPCL presented with ISS stage III compared to MM patients and had adverse genetic risk features such as significantly higher proportion of maf translocations [t(14;16) and t(14;20)], increased proportion of chromosome 1q gain, and fewer hyperdiploid patients. The gene discussed is MAF; the disease is Miyoshi myopathy.